CTOs on the Move

Osteal Therapeutics

www.ostealtx.com

 
Osteal Therapeutics is a privately-held, clinical-stage pharmaceutical company developing novel musculoskeletal therapeutics to treat orthopedic infections and their consequences.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.ostealtx.com
  • 4835 Lyndon B Johnson Freeway Suite 520
    Dallas, TX USA 75244
  • Phone: 469.809.2630

Executives

Name Title Contact Details

Funding

Osteal Therapeutics raised $30M on 03/08/2022

Similar Companies

The Bridgeway

The BridgeWay Hospital, located in Central Arkansas, offers an innovative recovery experience at the foothills of the Ouachita Mountains. Here, we offer a continuum of services designed to help children, adolescents, adults and seniors who are experien...

Abece

Abece is a Miami Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HatchMed

HatchMed - Bringing user centric design into the medical equipment world https://t.co/7vuyMSBnct #hospital #nurseproof #Seattle

Radius Health

Radius Health is driven by people who exhibit passion and commitment to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. We are a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius` lead product, TYMLOS (abaloparatide) Injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius` Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius clinical pipeline includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Radius` RAD140, a non-steroidal, selective androgen receptor modulator (SARM), is under investigation for potential use in hormone receptor positive breast cancer. Radius was founded in 2003 and has locations in Waltham and Cambridge, Massachusetts, Parsippany, New Jersey, and Wayne, Pennsylvania.